NDC 49884-125

Everolimus

Everolimus

Everolimus is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Par Pharmaceutical, Inc.. The primary component is Everolimus.

Product ID49884-125_bfe27c89-0c41-43ae-afad-32f27945fa10
NDC49884-125
Product TypeHuman Prescription Drug
Proprietary NameEverolimus
Generic NameEverolimus
Dosage FormTablet
Route of AdministrationORAL
Marketing Start Date2019-12-10
Marketing CategoryANDA / ANDA
Application NumberANDA207934
Labeler NamePar Pharmaceutical, Inc.
Substance NameEVEROLIMUS
Active Ingredient Strength5 mg/1
Pharm ClassesKinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],mTOR Inhibitor Immunosuppressant [EPC],mTOR Inhibitors [MoA],Decreased Immunologic Activity [PE]
NDC Exclude FlagN
Listing Certified Through2020-12-31

Packaging

NDC 49884-125-91

28 BLISTER PACK in 1 CARTON (49884-125-91) > 1 TABLET in 1 BLISTER PACK (49884-125-52)
Marketing Start Date2019-12-10
NDC Exclude FlagN
Sample Package?N

Drug Details

Active Ingredients

IngredientStrength
EVEROLIMUS5 mg/1

Pharmacological Class

  • Kinase Inhibitor [EPC]
  • Protein Kinase Inhibitors [MoA]
  • Cytochrome P450 3A4 Inhibitors [MoA]
  • P-Glycoprotein Inhibitors [MoA]
  • Cytochrome P450 2D6 Inhibitors [MoA]
  • mTOR Inhibitor Immunosuppressant [EPC]
  • mTOR Inhibitors [MoA]
  • Decreased Immunologic Activity [PE]

NDC Crossover Matching brand name "Everolimus" or generic name "Everolimus"

NDCBrand NameGeneric Name
0078-0566Afinitoreverolimus
0078-0567Afinitoreverolimus
0078-0594Afinitoreverolimus
0078-0620Afinitoreverolimus
0078-0626Afinitoreverolimus
0078-0627Afinitoreverolimus
0078-0628Afinitoreverolimus
49884-119EverolimusEverolimus
49884-125EverolimusEverolimus
49884-127EverolimusEverolimus
0078-0414Zortresseverolimus
0078-0415Zortresseverolimus
0078-0417Zortresseverolimus
0078-0422Zortresseverolimus

© 2020 FDA.report
This site is not affiliated with or endorsed by the FDA.